Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593188 · ClinicalTrials.gov registry record
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
A clinical trial of Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 264
- Enrollment target
- 20
- Study locations
NCT02593188: Completed study of Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire.
NCT02593188 is a study of Primary Immunodeficiency Diseases (PID) that has completed, run by Baxalta now part of Shire. The registered enrollment target is 264 participants, above the 35-participant average among 3 other Primary Immunodeficiency Diseases (PID) trials with a reported enrollment target (654% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02593188, a study of Primary Immunodeficiency Diseases (PID), has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 264 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the proposed study is to acquire additional data (including the assessment of anti-rHuPH20 antibodies) on the long-term safety of HYQVIA and to assess the prescribed treatment regimens and treatment administration in routine clinical practice.
Conditions Studied
Interventions
- BIOLOGICAL HYQVIA
Study Locations (20)
California
- Kern Allergy Medical Clinic - Bakersfield
- University of California Irvine Medical Center - Irvine
- Riviera Allergy Medical Center - Redondo Beach
- Capital Allergy & Respiratory Disease Center - Sacramento
- UCLA School of Medicine - Santa Monica
New York
- Corning Center for Clinical Research - Corning
- Northwell Health, Inc. PRIME - Great Neck
- Winthrop University - Mineola
- Columbia University Medical Center - New York
- Montefiore Medical Center - The Bronx
Colorado
- Asthma and Allergy Associates, PC - Colorado Springs
- Pikes Peak Allergy and Asthma - Colorado Springs
- IMMUNOe International Research Centers - Thornton
North Carolina
- Carolinas Healthcare System - Charlotte
- Allergy Asthma & Immunology Relief of Charlotte - Charlotte
Georgia
- Georgia Pollens Clinical Research Centers, Inc. - Albany
Massachusetts
- Boston Childrens Hospital - Boston
Michigan
- Canton Health Center - Canton
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2015-11-12 |
| Est. Completion | 2021-10-21 |
What the finished NCT02593188 record still lists
NCT02593188 is an observational study that tracks outcomes without assigning an intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, above the 35-participant average among 3 other Primary Immunodeficiency Diseases (PID) trials with a reported enrollment target (654% higher).
The record links to 1 condition, with Primary Immunodeficiency Diseases (PID) appearing as the primary indexed condition, and to 1 intervention - of which HYQVIA is the first listed.
NCT02593188 names 20 study sites across 9 states, led by California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT02593188 about?
NCT02593188 is a clinical study titled "Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)". The purpose of the proposed study is to acquire additional data (including the assessment of anti-rHuPH20 antibodies) on the long-term safety of HYQVIA and to assess the prescribed treatment regimens and treatment administration in routine clinical practice.
What is the current status of trial NCT02593188?
This trial is currently completed. The enrollment target is 264 participants. The study started on 2015-11-12. Estimated completion is 2021-10-21.
What conditions does trial NCT02593188 study?
This clinical trial studies the following conditions: Primary Immunodeficiency Diseases (PID).
What interventions are being tested in trial NCT02593188?
The interventions under investigation include: HYQVIA (BIOLOGICAL).
Who is sponsoring clinical trial NCT02593188?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02593188 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immunodeficiency Diseases (PID)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
RECRUITING · Phase 3
-
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
COMPLETED · Phase 1
-
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI